SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Strata Critical Medical, Inc. (SRTA) trades at a trailing P/E of 8.1. Trailing earnings yield is 12.27%. Graham Number is $6.18.
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (8.1); analyst target implies upside (+67.4%); earnings yield beats bond yields (12.27%).
- Trailing Earnings Yield 12.27% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $7.25 (+67.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 75/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SRTA
Valuation Multiples
P/E (TTM)8.1
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio1.21
P/S Ratio1.80
EV/EBITDA-17.7
Per Share Data
EPS (TTM)$0.50
Book Value / Share$3.38
Revenue / Share$2.39
FCF / Share$-0.72
Yields & Fair Value
Earnings Yield12.27%
Dividend Yield0.00%
Graham Number$6.18
SharesGrow IV$9.93 (+129.3%)
Analyst Target$7.25 (+67.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-6.7 |
0.00 |
14.47 |
2.32 |
- |
| 2020 |
-12.4 |
0.28 |
11.35 |
5.37 |
- |
| 2021 |
-18.2 |
0.61 |
2.50 |
14.43 |
- |
| 2022 |
-9.4 |
0.28 |
0.93 |
1.75 |
- |
| 2023 |
-4.6 |
-0.05 |
1.11 |
1.15 |
- |
| 2024 |
-12.1 |
0.22 |
1.48 |
1.32 |
- |
| 2025 |
9.6 |
-0.04 |
1.42 |
2.01 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-1.47 |
$31.2M |
$-10.84M |
-34.7% |
| 2020 |
$-0.81 |
$23.43M |
$-10.16M |
-43.4% |
| 2021 |
$-0.57 |
$50.53M |
$-40.05M |
-79.3% |
| 2022 |
$-0.38 |
$146.12M |
$-27.26M |
-18.7% |
| 2023 |
$-0.76 |
$225.18M |
$-56.08M |
-24.9% |
| 2024 |
$-0.35 |
$248.69M |
$-27.31M |
-11% |
| 2025 |
$0.50 |
$197.14M |
$41.35M |
21% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.10 |
$-0.10 – $-0.10 |
$269.18M |
$267.83M – $270.16M |
1 |
| 2027 |
$-0.01 |
$-0.01 – $-0.01 |
$293.66M |
$290.55M – $295.37M |
2 |
| 2028 |
$0.00 |
$0.00 – $0.00 |
$318M |
$316.4M – $319.16M |
1 |
